CompletedNCT00790777

A Study of the Bioequivalence of 12 mg Paliperidone Extended Release Tablets Manufactured at Gurabo and Vacaville

Medication studyAges 18–55Schizophrenia

The study in practice

Understand this study

This study was for healthy volunteers. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.

Study clarity

Study start dateMarch 2007

Recruitment status: Completed
Enrollment listed in the registry: 72
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Sponsor type: Pharmaceutical company
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 1
Locations: Not clearly listed
Age range: From 18 Years to 55 Years
Official registry ID: NCT00790777
Official title: Show the full official title
A Single-dose, Open-label, Randomized, 2-way Crossover Pivotal Bioequivalence Study of 12 mg Paliperidone Extended Release Tablets Manufactured at Gurabo and Vacaville Under Fasted Condition in Healthy Subjects

Completed

Locations not listed

FAQ

Who is behind this study?

The study sponsor is Johnson & Johnson Pharmaceutical Research & Development, L.L.C., a pharmaceutical company.

Did this study involve medication?

Yes. The study involved medication, including Paliperidone ER.

Who was this study for?

This study was for healthy volunteers. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.